Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Although plasmapheresis is becoming standard practice as a rescue therapy for neuromyelitis optica (NMO), evidence for the therapeutic efficacy of plasmapheresis is limited, and the effect of plasmapheresis on anti-aquaporin-4 (AQP4) levels in patients with NMO has not been reported. Here, our objective was to evaluate the clinical efficacy of therapeutic plasmapheresis and its effect on anti-AQP4 antibody levels in patients with NMO spectrum disorder (NMOSD). Methods We retrospectively reviewed the medical records of 15 patients with NMOSD who had 18 acute attacks and received plasmapheresis because they did not respond to high-dose intravenous methylprednisolone (IVMP) therapy. Anti-AQP4 antibodies were measured before and after plasmapheresis. The primary outcomes were functional improvements immediately and 6 months after plasmapheresis, and the secondary outcome was the change in anti-AQP4antibody serum levels following plasmapheresis. Results Plasmapheresis following IVMP therapy led to significant improvement in 50% of the 18 attacks in 15 patients immediately after the procedure was completed, and in 78% (14attacks) after 6 months. Plasmapheresis was generally well tolerated in all patients. Anti-AQP4antibody serum levels declined significantly following plasmapheresis, to a mean of 15% of the preplasmapheresis levels. Lower scores on the visual outcome scale recorded before an attack were associated with significant immediate improvement upon the completion of plasmapheresis (p=0.03). Conclusions Plasmapheresis following IVMP therapy effectively removed anti-AQP4 antibodies and was accompanied by a substantial improvement in the neurological disability of patients with NMOSD. Lower levels of pre-existing neurological damage may be associated with an improved acute response to plasmapheresis.
Abstract
Background and Purpose Although plasmapheresis is becoming standard practice as a rescue therapy for neuromyelitis optica (NMO), evidence for the therapeutic efficacy of plasmapheresis is limited, and the effect of plasmapheresis on anti-aquaporin-4 (AQP4) levels in patients with NMO has not been reported. Here, our objective was to evaluate the clinical efficacy of therapeutic plasmapheresis and its effect on anti-AQP4 antibody levels in patients with NMO spectrum disorder (NMOSD). Methods We retrospectively reviewed the medical records of 15 patients with NMOSD who had 18 acute attacks and received plasmapheresis because they did not respond to high-dose intravenous methylprednisolone (IVMP) therapy. Anti-AQP4 antibodies were measured before and after plasmapheresis. The primary outcomes were functional improvements immediately and 6 months after plasmapheresis, and the secondary outcome was the change in anti-AQP4antibody serum levels following plasmapheresis. Results Plasmapheresis following IVMP therapy led to significant improvement in 50% of the 18 attacks in 15 patients immediately after the procedure was completed, and in 78% (14attacks) after 6 months. Plasmapheresis was generally well tolerated in all patients. Anti-AQP4antibody serum levels declined significantly following plasmapheresis, to a mean of 15% of the preplasmapheresis levels. Lower scores on the visual outcome scale recorded before an attack were associated with significant immediate improvement upon the completion of plasmapheresis (p=0.03). Conclusions Plasmapheresis following IVMP therapy effectively removed anti-AQP4 antibodies and was accompanied by a substantial improvement in the neurological disability of patients with NMOSD. Lower levels of pre-existing neurological damage may be associated with an improved acute response to plasmapheresis.
참고문헌 (25)
- Lehmann HC, "Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders", Archives of neurology, 63, pp.930~935 (2006)
- Lennon VA, "A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis", The Lancet, 364, pp.2106~2112 (2004)
- Saadoun S, "Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice", Brain, 133, pp.349~361 (2010)
- Weinshenker BG, "Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis", Annals of Neurology, 59, pp.566~569 (2006)
- Matiello M, "NMO-IgG predicts the outcome of recurrent optic neuritis", Neurology, 70, pp.2197~2200 (2008)
- Bennett JL, "Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica", Annals of Neurology, 66, pp.617~629 (2009)
- Bradl M, "Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo", Annals of Neurology, 66, pp.630~643 (2009)
- 김우준, "New Insights into Neuromyelitis Optica", Journal of Clinical Neurology, 7(3), pp.115~127 (2011), 대한신경과학회
- Keegan M, "Plasma exchange for severe attacks of CNS demyelination: predictors of response", Neurology, 58, pp.143~146 (2002)
- Llufriu S, "Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months", Neurology, 73, pp.949~953 (2009)
- Magaña SM, "Beneficial plasma exchange response in central nervous system inflammatory demyelination", Archives of neurology, 68, pp.870~878 (2011)
- Watanabe S, "Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica", Multiple Sclerosis Journal, 13, pp.128~132 (2007)
- Wang KC, "The rescue effect of plasma exchange for neuromyelitis optica", Journal of Clinical Neuroscience, 18, pp.43~46 (2011)
- Collongues N, "Current and future treatment approaches for neuromyelitis optica", Therapeutic Advances in Neurological Disorders, 4, pp.111~121 (2011)
- Sellner J, "EFNS guidelines on diagnosis and management of neuromyelitis optica", European Journal of Neurology, 17, pp.1019~1032 (2010)
- Szczepiorkowski ZM, "Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis", Journal of Clinical Apheresis, 25, pp.83~177 (2010)
- Wingerchuk DM, "Revised diagnostic criteria for neuromyelitis optica", Neurology, 66, pp.1485~1489 (2006)
- Wingerchuk DM, "The spectrum of neuromyelitis optica", The Lancet Neurology, 6, pp.805~815 (2007)
- Wingerchuk DM, "The clinical course of neuromyelitis optica (Devic’s syndrome)", Neurology, 53, pp.1107~1114 (1999)
- Kim W, "Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4", Multiple Sclerosis Journal, 18, pp.578~586 (2012)
- Narita YM, "Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?", The Journal of Dermatology, 38, pp.236~245 (2011)
- Bonnan M, "Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder", Multiple Sclerosis Journal, 15, pp.487~492 (2009)
- Brecher ME, "Plasma exchange: why we do what we do", Journal of Clinical Apheresis, 17, pp.207~211 (2002)
- Bonnan M, "Plasma exchange in severe attacks of neuromyelitis optica", Multiple Sclerosis International, 2012, pp.787630~ (2012)
- Okafor C, "Introduction and overview of therapeutic apheresis", Journal of Clinical Apheresis, 25, pp.240~249 (2010)